Skip to content

A Research Study to See How Much CagriSema (1.0 mg Once Weekly) Lowers Blood Sugar and Body Weight Compared to Tirzepatide (5 mg Once Weekly) in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both

Diabetes Mellitus, Type 2

This study will look at how much CagriSema lowers blood sugar and body weight in people with type 2 diabetes. CagriSema is a new investigational medicine. Doctors cannot yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide. Doctors can prescribe tirzepatide in some countries. Participants will either receive CagriSema or tirzepatide. Which treatment the participant will receive is decided by chance. For each participant, the study will last for up to 1 year and 4 months.

null

Conditions de participation

  • Sexe:

    ALL
  • Âges admissibles:

    18 and up

Critères de participation

Inclusion Criteria:

* Male or female (sex at birth).
* Age 18 years or above at the time of signing the informed consent.
* Diagnosed with type 2 diabetes mellitus greater than or equal to (\>=) 180 days before screening.
* Stable daily dose(s) \>= 90 days before screening of any of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator:
* Metformin
* sodium-glucose co-transporter 2 inhibitor (SGLT2i)
* Glycated haemoglobin (HbA1c) 7.0-10.5 percent (53-91 millimoles per mol \[mmol/mol\]) (both inclusive) as determined by central laboratory at screening.
* Body mass index (BMI) \>= 30 kilogram per square meter (kg/m\^2) at screening. BMI will be calculated in the electronic case report form (eCRF) based on height and body weight at screening.

Exclusion Criteria:

* Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using a highly effective contraceptive method.
* Renal impairment with estimated Glomerular Filtration Rate less than \< 30 milliliter per minute per 1.73 square meter (mL/min/1.73 m\^2) as determined by central laboratory at screening.
* Treatment with any anti-diabetic or anti-obesity medication (irrespective of indication) other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days is allowed.
* Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by an eye examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.

Lieu de l'étude

Hilltop Medical Clinic
Hilltop Medical Clinic
Surrey, British Columbia
Canada

Contactez l'équipe d'étude

Wharton Med Clin Trials
Wharton Med Clin Trials
Hamilton, Ontario
Canada

Contactez l'équipe d'étude

Alpha Recherche Clinique - Clinique de Levis
Alpha Recherche Clinique - Clinique de Levis
Levis, Quebec
Canada

Contactez l'équipe d'étude

Centricity Research Etobicoke
Centricity Research Etobicoke
Etobicoke, Ontario
Canada

Contactez l'équipe d'étude

Ctr de rech Clin de Laval
Ctr de rech Clin de Laval
Laval, Quebec
Canada

Contactez l'équipe d'étude

Diex Recherche Victoriaville
Diex Recherche Victoriaville
Victoriaville, Quebec
Canada

Contactez l'équipe d'étude

G.A. Research Associates Ltd.
G.A. Research Associates Ltd.
Moncton, New Brunswick
Canada

Contactez l'équipe d'étude

London Road Diagnostic Clinic and Medical Centre
London Road Diagnostic Clinic and Medical Centre
Sarnia, Ontario
Canada

Contactez l'équipe d'étude

Centre Medical Acadie
Centre Medical Acadie
Montreal, Quebec
Canada

Contactez l'équipe d'étude

Centricity Research Brampton
Centricity Research Brampton
Brampton, Ontario
Canada

Contactez l'équipe d'étude

Diabetes Heart Research Centre
Diabetes Heart Research Centre
Toronto, Ontario
Canada

Contactez l'équipe d'étude

Ctr de Med Metab de Lanaudiere
Ctr de Med Metab de Lanaudiere
Terrebonne, Quebec
Canada

Contactez l'équipe d'étude

Étude parrainée par
Novo Nordisk A/S
Participants recherchés
Plus d'informations
ID de l'étude: NCT06534411